ABT-072
- Generic Name
- ABT-072
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27N3O5S
- CAS Number
- 1132936-00-5
- Unique Ingredient Identifier
- PSQ4R5K1QI
- Background
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
- Associated Conditions
- -
- Associated Therapies
- -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
- Conditions
- Interventions
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 11
- Registration Number
- NCT01221298
- Locations
- 🇺🇸
Site Reference ID/Investigator# 43182, Seattle, Washington, United States
🇺🇸Site Reference ID/Investigator# 41128, Los Angeles, California, United States
🇺🇸Site Reference ID/Investigator# 42262, Chicago, Illinois, United States
A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2010-10-25
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT01081483
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 74
- Registration Number
- NCT01074008
- Locations
- 🇺🇸
Site Reference ID/Investigator# 23370, Anaheim, California, United States
🇺🇸Site Reference ID/Investigator# 23387, La Jolla, California, United States
🇺🇸Site Reference ID/Investigator# 23388, Los Angeles, California, United States
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Abbott
- Target Recruit Count
- 52
- Registration Number
- NCT00982826
- Locations
- 🇺🇸
Site Reference ID/Investigator# 23742, Waukegan, Illinois, United States
Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Abbott
- Target Recruit Count
- 18
- Registration Number
- NCT00947440
- Locations
- 🇺🇸
Site Reference ID/Investigator# 22384, Waukegan, Illinois, United States
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Abbott
- Target Recruit Count
- 32
- Registration Number
- NCT00890318
- Locations
- 🇺🇸
Abbott Clinical Pharmaceutical Research Unit, Waukegan, Illinois, United States
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 5
- Registration Number
- NCT00872196
- Locations
- 🇺🇸
Site Reference ID/Investigator# 18222, Los Angeles, California, United States
A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Abbott
- Target Recruit Count
- 100
- Registration Number
- NCT00752687
- Locations
- 🇺🇸
Global Medical Information, Abbott Park, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.